Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade plus high-dose dexamethasone as first-line therapy in multiple myeloma ≤65 years
2005-004874-26Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Nov 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and dexamethasone in multiple myeloma (MM), sponsored by IRCCS San Matteo Foundation. Primary endpoint: Complete remission rate. Started Nov 2005; status: completed.
02
Drugs
bortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-004874-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004874-26.